About Darwin

American healthcare is ƒu¢keδ.
Time for change.

What Darwin is

Darwin is a direct-to-consumer healthcare company.

We make the things people actually use to look after themselves — nutrition, everyday essentials, and the tools to see whether any of it is working — and we sell them directly, at a price printed on the page.

We are starting with people using GLP-1s, because that is where the questions are newest and the need is sharpest. We are not building only for that moment. Bodies and circumstances keep changing, and the point is to still be useful when they do.

Mission

To give anyone direct, affordable access to the healthcare they want — without gatekeepers, hidden prices, or guesswork.

Vision

A world where healthcare works for patients: proactive, transparent, affordable, and science-driven.

What we believe

Four things we think are true about American healthcare, and why they add up to an opening.

Most people would rather run their own health than be managed through it.

The system is built as though the person is the passive part — booked, referred, prescribed to, and told the price afterwards, if at all. That is not what we see. People are already reading the studies, tracking what they eat, comparing what they are told against what actually happens to them, and arriving with better questions than a ten-minute appointment has room for.

Give someone a real price, honest evidence and a tool that measures something true, and they will do a great deal of the work themselves.

American healthcare is not a market, whatever it calls itself.

A market needs buyers who can see prices and sellers who are allowed to compete. American healthcare is thin on both. Hospitals have been required by federal rule to publish their prices since 2021, and five years on, independent reviews still put full compliance somewhere between a third and a half of hospitals — while the GAO reported in 2025 that CMS still cannot vouch for whether the data that is published is complete or accurate.

A price you cannot see is a price you cannot compare, and a price nobody can compare never has to come down. Add a supply of clinicians and facilities that is deliberately constrained, and you get something using the vocabulary of a free market while working like the opposite of one. The people paying for it are the only participants with no leverage.

GLP-1s are a genuine breakthrough, and they changed who is holding the pen.

Not marketing enthusiasm. In the SELECT trial — 17,604 adults with overweight or obesity and established cardiovascular disease, none of them diabetic — semaglutide reduced major adverse cardiovascular events from 8.0% to 6.5% over roughly three years. That is a hard clinical outcome, not a cosmetic one, and it is why this category is treated differently from the decades of weight-loss products before it.

The second-order effect matters as much as the first. Millions of people who were not previously engaged with their own health now are — many paying out of pocket, choosing for themselves, and asking what else can be bought this directly.

Buying directly is how the door opens.

When someone pays directly, a price has to exist and be defensible. Products have to be worth choosing again rather than merely prescribed. Evidence has to be legible to the person spending the money, not only to an intermediary.